CPT 81227 CYP2C9 Reimbursement & Policy | OpenPayer

Summary & Overview

CPT 81227: CYP2C9 Genetic Test for Drug Metabolism

CPT code 81227 denotes a molecular diagnostic laboratory assay to detect common variants in the CYP2C9 gene, a key enzyme in drug metabolism. Nationally, reporting and coverage of pharmacogenomic tests such as this are important for medication safety and personalized therapy decisions, particularly for drugs with narrow therapeutic indices or dose adjustments affected by CYP2C9 variants.

Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies and prior authorization requirements for pharmacogenomic testing vary by payer, affecting access and utilization.

Readers will find a concise clinical context for the test, an overview of service settings and typical use cases, and a summary of the payer landscape covered in this analysis. Benchmarks and policy trends relevant to molecular diagnostic and pharmacogenomic services are summarized, along with operational considerations for laboratories submitting claims for CPT code 81227. Data not available in the input are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareCPT 81227pharmacogenomicsCYP2C9molecular-diagnosticslaboratory-testingprecision-medicineclinical-genetics

Billing Code Overview

CPT code 81227 describes a laboratory test performed by a lab analyst to detect the presence of common variants in the gene cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9). This is a molecular diagnostic assay that identifies genetic changes affecting drug metabolism.

Service Type: Genetic testing — molecular diagnostic assay

Typical Site of Service: Clinical laboratory or reference laboratory

Data not available in the input for payers, taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A 52-year-old patient with a history of atrial fibrillation is evaluated by their cardiology clinic to guide warfarin dosing and bleeding risk. The clinician orders genetic testing for cytochrome P450 2C9 (CYP2C9) variants to detect common polymorphisms that affect warfarin metabolism. A venous blood sample is collected at an outpatient laboratory, sent to a molecular diagnostics lab, and the technical component test 81227 is performed to detect common CYP2C9 gene variants (for example *2, *3 alleles). The lab analyst runs the assay, generates raw data, performs quality control, and provides a technical report to the interpreting laboratory physician. The interpreting physician integrates the technical result with clinical information (other pharmacogenomic results, current medications, INR history) and issues a consult note with dosing guidance.

Typical site of service: outpatient hospital laboratory, reference molecular diagnostics laboratory, or hospital clinical lab performing targeted pharmacogenetic testing.

Typical workflow steps:

Order placed by cardiology or primary care provider
Specimen collection (venipuncture) at outpatient lab
Specimen accessioning and DNA extraction in molecular lab
Technical testing (81227) performed and raw data QC
Result forwarded to interpreting clinician for final report and incorporation into medication management

Related Codes

CPT-81216-BRCA2-FULL-GENE-SEQUENCING

CPT 81216: BRCA2 Full-Gene Sequencing

CPT-81298-MSH6-FULL-GENE-SEQUENCING

CPT 81298: Full-Gene Sequencing for MSH6

CPT-81184-CACNA1A-EXPANDED-SEQUENCE-CHARACTERIZATION

CPT 81184: CACNA1A Expanded Sequence Characterization

CPT-81194-NTRK-TRANSLOCATION-TESTING-FFPE-TISSUE

CPT 81194: NTRK Translocation Analysis on FFPE Tumor Tissue

CPT-81108-HPA-4-R143Q-GENOTYPING

CPT 81108: HPA-4 (R143Q) Genotyping, Technical Component

CPT-81343-PPP2R2B-REPEAT-EXPANSION-TEST

CPT 81343: PPP2R2B Repeat Expansion Detection, Molecular Diagnostic

CPT-81357-U2AF1-MUTATION-ANALYSIS-HEMATOLOGIC-DISORDERS

CPT 81357: U2AF1 Mutation Analysis for Hematologic Disorders

CPT-81203-APC-GENE-INSERTION-DELETION-ANALYSIS

CPT 81203: APC Gene Insertion/Deletion Analysis

CPT-81318-PMS2-TARGETED-FAMILIAL-MUTATION-ANALYSIS

CPT 81318: PMS2 Targeted Familial Mutation Analysis

CPT-81249-G6PD-GENE-FULL-SEQUENCE-ANALYSIS

CPT 81249: Full G6PD Gene Sequencing

Showing 1–10 of 199

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When billing only the physician interpretation component separate from the lab's technical component (rare for molecular lab technical-only CPT).
`TC`	Technical component	When billing only the laboratory technical component of the test (commonly appended to lab-only reports).
`90`	Reference (outside) laboratory	When the performing laboratory is a reference lab and billing is done by the patient’s ordering provider or another entity.
`91`	Repeat clinical diagnostic lab test (Note: not in provided list)	Data not available in the input.
`59`	Distinct procedural service	When this molecular test is a distinct service from another procedure on the same day requiring separate reporting.
`62`	Two surgeons (Note: limited relevance)	When two qualified labs/providers share responsibility for interpretation; rarely used for lab tests.
`52`	Reduced services	When the test is partially performed or limited compared to the full protocol.
`53`	Discontinued procedure	If the test processing was started but discontinued for valid clinical/lab reasons.
`80`	Assistant surgeon	Not typically applicable to lab testing but included when a secondary professional component is billed.
`90`	Reference lab	Duplicate entry removed; see `90` above.
`QX`	Modifier for CLIA-qualified personnel (Note: specific to certain services)	When services are performed by a CLIA-qualified physician/clinical staff under Medicare rules.
`QY`	Under certain payer programs (Note: payer-specific)	When required by payer to indicate laboratory or network-specific conditions.
`59`	Distinct procedural service	Duplicate entry removed; see `59` above.

Taxonomy Code	Specialty	Notes
207RH0000X	Clinical Laboratory Molecular Pathology	Molecular diagnostics laboratories and laboratory directors performing `CYP2C9` testing.
2084P0800X	Clinical Pathology	Pathologists overseeing laboratory testing and result interpretation.
207L00000X	Medical Laboratory Technician/Technologist	Laboratory professionals performing the technical assay (`81227`).
208D00000X	Cardiology	Ordering clinicians who request pharmacogenetic testing to guide anticoagulant therapy.
207K00000X	Clinical Genetics	Genetics professionals who may consult on pharmacogenomic interpretation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I48.0`	Paroxysmal atrial fibrillation	Common indication for warfarin; `CYP2C9` testing informs warfarin metabolism and dosing.
`I48.1`	Persistent atrial fibrillation	Long-term anticoagulation may be needed; genetic variants affect dose requirements.
`I48.91`	Unspecified atrial fibrillation	Frequently the clinical reason to evaluate anticoagulant metabolism via `CYP2C9`.
`Z79.01`	Long term (current) use of anticoagulants	Monitoring and dosing guidance for chronic warfarin therapy may prompt `CYP2C9` testing.
`D68.9`	Coagulation defect, unspecified	Evaluation of bleeding risk and anticoagulant metabolism can include pharmacogenetic testing.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81225`	CYP2C19 gene analysis, common variants	Often ordered alongside `81227` when assessing multiple pharmacogenes affecting antiplatelet or anticoagulant therapy.
`81226`	VKORC1 gene analysis, common variants	Commonly performed with `81227` to guide warfarin dosing (VKORC1 influences warfarin sensitivity).
`0033U`	Molecular pathology procedure (example molecular assay)	May be used for alternative or multiplex pharmacogenetic panels that include `CYP2C9` variants; ordered when broader panel testing is indicated.
`80500`	Drug assay (e.g., therapeutic drug monitoring)	May be performed before or after genetic testing to monitor warfarin effect (INR measured by separate labs) or other drug levels.
`81025`	Urinalysis (automated)	Ancillary lab testing sometimes ordered as part of pre-procedural evaluation; not specific but often present in comprehensive workups.